… of care, but the role of patient gender on treatment outcome is unclear. We aimed to assess
the efficacy of immunotherapy according to patient gender in advanced kidney cancer. …

… In this Review, we discuss the use of ICI in kidney cancer. We provide an overview of the
preclinical rationale and mechanisms of ICI specific to kidney cancer and summarize the …

… answers to guide us in selecting treatments for our patients. In this review, we shed light on
advances in immunotherapy that revolutionized the RCC treatment landscape and described …

… Eighty-nine nephrectomized MRCC patients not treated with immunotherapy represent our
historical controls. All patients were treated and monitored in our institution; in 39 patients, the …

… immunotherapy has resulted in long-term disease-free survival in a small proportion of patients
… This comprehensive review aims at describing the different immunotherapy modalities in …

… In the immunotherapy era, PD-L1 expression by IHC … cancer where PD-L1 expression is
incorporated in treatment decisions, 28 the role of PD-L1 expression in directing kidney cancer …

… What melanoma, lung and kidney cancers have in common are … tumour types, focusing on
both cancer vaccines and on agents that … to immunotherapy in kidney cancer, lung cancer and …

… describe the causes of acute kidney injury in recipients of cancer immunotherapy (Figure 1)
(… cancer immunotherapies (Table 1), but readers must keep in mind that immunotherapy is a …

… Improved biomarkers for patient selection, tumor vaccines and combination therapy may …
of existing immunotherapies. This review summarizes recent progress in immunotherapy for …

… With the advent of ICI we have entered an exciting era in kidney cancer treatment, and we
remain optimistic regarding its expanding role. While the present trial is an important step in …